Home › Compare › CWPWF vs ABBV
CWPWF yields 11.16% · ABBV yields 3.06%● Live data
📍 CWPWF pulled ahead of the other in Year 1
Combined, CWPWF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CWPWF + ABBV for your $10,000?
Concord New Energy Group Limited, an investment holding company, engages in the generation of power in the People's Republic of China and internationally. The company operates through Power Generation, Intelligent Operation and Maintenance, and Others segments. It is involved in the investment, engineering, procurement, construction, operation, and maintenance of wind and solar power plants; and provision of design, technical, and consultancy services. The company also engages in the sale of solar and new energy equipment; design, research, and exploitation of power systems; leasing of equipment; and investment and operation of solar and wind power plants. In addition, it provides finance lease services and energy internet services. The company sells its electric power to external power grid companies. As of December 31, 2021, it had 70 grid-connected wind and photovoltaic power plants with a total installed capacity of approximately 3,708 megawatts, which include 54 wind power plants with an installed capacity of 3,313 megawatts, as well as 16 photovoltaic power plants with an installed capacity of 394 megawatts. The company was formerly known as China Windpower Group Limited and changed its name to Concord New Energy Group Limited in March 2015. The company was founded in 2006 and is based in Admiralty, Hong Kong.
Full CWPWF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.